Evaxion to present 3-year cancer vaccine data at ESMO 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
July 17, 2026 7:15 AM EDTThree-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into the vaccines effect also as stand-alone treatment of patients with advanced melanomaUnprecedented two-year data from the trial presented last year showed high response rates and an impressive durability of responses
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (Evaxion), a clinical-stage TechBio company... More
